1. Matrix-Metalloproteinase-2 Predicts Arteriovenous Fistula Failure in Hemodialysis Patients
- Author
-
Crina Rusu, Ioan Mihai Paţiu, Dan Ştefan Vlăduţiu, Laura Pop, Diana Moldovan, Dacian Tirinescu, Cosmina Ioana Bondor, Alina Potra, Ciprian Tomuleasa, and Ina Maria Kacso
- Subjects
medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Fistula ,030232 urology & nephrology ,Vascular access ,Arteriovenous fistula ,Hematology ,030204 cardiovascular system & hematology ,Matrix metalloproteinase ,medicine.disease ,Pathophysiology ,Surgery ,03 medical and health sciences ,Stenosis ,0302 clinical medicine ,Nephrology ,Internal medicine ,Cardiology ,Medicine ,Hemodialysis ,business ,Dialysis - Abstract
In hemodialysis patients the principal cause of arteriovenous fistula dysfunction is stenosis. Matrix-metalloproteinase-2 is implicated in the pathophysiological mechanism of stenosis development. Our study tried to assess the clinical impact of this protease on arteriovenous fistula survival. Seventy-nine prevalent dialysis patients with functional arteriovenous fistulas were included in the study. The presence of stenosis and the serum levels of matrix-metalloproteinase-2 were determined at the beginning of the study. The patency of the arteriovenous fistulas was followed- up for two years. In multivariate regression; matrix-metalloproteinase-2 was a significant predictor of vascular access loss (HR = 1.104, 95%CI 1.033-1.179, P = 0.003). Patients with a level of matrix-metalloproteinase-2 lower than 50 ng/mL had a better survival of the arteriovenous fistulas. Matrix-metalloproteinase-2 was an even stronger predictor of fistula failure in the stenosis group (HR = 1.076, 95%CI 1.027-1.127, P = 0.002). In our study matrix-metalloproteinase-2 has a predictive value for arteriovenous fistula failure.
- Published
- 2017
- Full Text
- View/download PDF